Completion of Offering and Increase in Registered Capital
MEDIROM Healthcare Technologies (NASDAQ: MRM) has completed all corporate capital registration procedures for its offering of 2,860,000 common shares represented by American Depositary Shares. The offering, which closed on December 11, 2024, generated gross proceeds of approximately $5 million.
Following the registration completion on January 14, 2025, the company's registered corporate capital and capital reserve amounts are 365,019,146 yen and 365,019,145 yen respectively, with 7,994,451 total outstanding shares. This marks the first follow-on registered underwritten public offering in the United States by a Japanese company listed solely on a U.S. stock exchange.
The proceeds will be used for working capital and general corporate purposes, including potential investments, acquisitions, strategic collaborations to expand customer base, and development and marketing of new services.
MEDIROM Healthcare Technologies (NASDAQ: MRM) ha completato tutte le procedure di registrazione del capitale societario per l'offerta di 2.860.000 azioni ordinarie rappresentate da American Depositary Shares. L'offerta, che si è chiusa l'11 dicembre 2024, ha generato ricavi lordi di circa 5 milioni di dollari.
Dopo il completamento della registrazione il 14 gennaio 2025, il capitale sociale registrato dell'azienda e i fondi di capitale ammontano rispettivamente a 365.019.146 yen e 365.019.145 yen, con 7.994.451 azioni in circolazione. Si tratta della prima offerta pubblica sottoscritta consecutiva registrata negli Stati Uniti da una società giapponese quotata esclusivamente su una borsa valori statunitense.
I proventi saranno utilizzati per il capitale di esercizio e per scopi aziendali generali, inclusi potenziali investimenti, acquisizioni, collaborazioni strategiche per espandere la base di clienti, e lo sviluppo e marketing di nuovi servizi.
MEDIROM Healthcare Technologies (NASDAQ: MRM) ha completado todos los procedimientos de registro de capital corporativo para su oferta de 2,860,000 acciones comunes representadas por American Depositary Shares. La oferta, que cerró el 11 de diciembre de 2024, generó ingresos brutos de aproximadamente 5 millones de dólares.
Tras la finalización del registro el 14 de enero de 2025, el capital social registrado de la empresa y las reservas de capital son de 365,019,146 yenes y 365,019,145 yenes respectivamente, con un total de 7,994,451 acciones en circulación. Esto marca la primera oferta pública registrada bajo suscripción en los Estados Unidos por una empresa japonesa que cotiza exclusivamente en una bolsa de valores estadounidense.
Los ingresos se utilizarán para capital de trabajo y fines corporativos generales, incluidos posibles inversiones, adquisiciones, colaboraciones estratégicas para expandir la base de clientes, y el desarrollo y marketing de nuevos servicios.
MEDIROM Healthcare Technologies (NASDAQ: MRM)는 American Depositary Shares로 대표되는 2,860,000주의 보통주 제공을 위한 모든 기업 자본 등록 절차를 완료했습니다. 이 제공은 2024년 12월 11일에 마감되었으며, 약 500만 달러의 총 수익을 발생시켰습니다.
2025년 1월 14일 등록 완료 이후, 회사의 등록된 자본금과 자본 준비금은 각각 365,019,146엔과 365,019,145엔이며, 7,994,451주의 발행된 총 주식이 있습니다. 이는 미국의 증권 거래소에만 상장된 일본 회사의 첫 번째 후속 공모 등록으로 기록됩니다.
수익은 운영 자본 및 일반 회사 목적에 사용될 예정이며, 이는 잠재적인 투자, 인수, 고객 기반 확대를 위한 전략적 협력, 그리고 새로운 서비스의 개발 및 마케팅을 포함합니다.
MEDIROM Healthcare Technologies (NASDAQ: MRM) a terminé toutes les procédures d'enregistrement du capital social pour son offre de 2.860.000 actions ordinaires représentées par des American Depositary Shares. L'offre, qui s'est clôturée le 11 décembre 2024, a généré des produits bruts d'environ 5 millions de dollars.
Après l'achèvement de l'enregistrement le 14 janvier 2025, le capital social enregistré de l'entreprise et le fonds de capital s'élèvent respectivement à 365.019.146 yens et 365.019.145 yens, avec un total de 7.994.451 actions en circulation. Cela marque la première offre publique enregistrée souscrite aux États-Unis par une entreprise japonaise cotée exclusivement sur une bourse américaine.
Les produits seront utilisés pour le capital de fonctionnement et les objectifs généraux de l'entreprise, y compris des investissements potentiels, des acquisitions, des collaborations stratégiques pour élargir la base de clients, ainsi que le développement et le marketing de nouveaux services.
MEDIROM Healthcare Technologies (NASDAQ: MRM) hat alle Verfahren zur Registrierung des Gesellschaftskapitals für das Angebot von 2.860.000 Stammaktien, die durch American Depositary Shares repräsentiert werden, abgeschlossen. Das Angebot, das am 11. Dezember 2024 abgeschlossen wurde, erzielte einen Bruttoerlös von etwa 5 Millionen Dollar.
Nach Abschluss der Registrierung am 14. Januar 2025 betragen das registrierte Gesellschaftskapital und die Kapitalrücklage des Unternehmens 365.019.146 Yen bzw. 365.019.145 Yen, mit insgesamt 7.994.451 ausstehenden Aktien. Dies ist das erste nachfolgende registrierte öffentliche Angebot in den Vereinigten Staaten von einem japanischen Unternehmen, das ausschließlich an einer US-Börse notiert ist.
Die Erlöse werden für Betriebskapital und allgemeine Unternehmenszwecke verwendet, einschließlich möglicher Investitionen, Akquisitionen, strategischer Kooperationen zur Erweiterung der Kundenbasis sowie der Entwicklung und Vermarktung neuer Dienstleistungen.
- Successfully raised $5 million through share offering
- First Japanese company listed solely on US exchange to complete follow-on offering
- Proceeds to fund expansion, acquisitions, and new service development
- Share dilution due to issuance of 2,860,000 new shares
Insights
The completion of MEDIROM's
Breaking this down in simple terms: imagine a pizza cut into 5 slices and then adding 3 more slices. While there's more pizza overall (more capital for the company), each original slice becomes relatively smaller (dilution for existing shareholders). The
The historical significance of this being potentially the first follow-on registered underwritten public offering in the U.S. by a Japan-only listed company adds a unique angle to this transaction. This pioneering move could pave the way for other Japanese companies seeking U.S. capital markets access, though the relatively small size of the offering and the company's micro-cap status may limit its precedential value.
The strategic implications of this capital raise deserve careful scrutiny. With a market cap of approximately
Think of this like a small business getting a large loan - it's significant money that could fuel growth, but success depends entirely on how it's used. The mention of potential acquisitions, strategic collaborations and new service development suggests an aggressive growth strategy, but at this valuation level, meaningful M&A opportunities may be
The timing and execution of this offering amid challenging market conditions for micro-cap stocks demonstrates management's ability to secure funding, though the dilutive impact on shareholders is substantial. The key to justifying this dilution will be management's execution in deploying this capital efficiently to generate returns exceeding the cost of equity.
TOKYO, Jan. 21, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (the “Company” or “MEDIROM”), a health technology and holistic healthcare company headquartered in Tokyo, Japan and led by CEO Kouji Eguchi, announces that, on January 14, 2025, all corporate capital registration procedures under Japanese law were completed with respect to the Company’s offering of 2,860,000 common shares represented by American Depositary Shares, generating gross proceeds of approximately
The Company believes that this offering marks the first follow-on registered underwritten public offering in the United States by a Japanese company listed solely on a U.S. stock exchange.
Purpose of the Offering
The Company intends to use the proceeds from the offering for working capital and general corporate purposes, which may include investments, acquisitions, or strategic collaborations to expand its customer base, as well as the development and marketing of new services.
As a company primarily engaged in business activities within Japan, MEDIROM will continue to focus on improving the profitability and growth of its group business to meet the expectations of its investors, including U.S. investors and those who participated in the public offering.
No Offer or Solicitation
This press release and the information contained herein are not, and do not, constitute an offer to sell any securities or a solicitation of an offer to buy any securities in the United States or any other state or jurisdiction, nor shall any securities be offered or sold in any jurisdiction in which such an offer, solicitation or sale would be unlawful.
About MEDIROM Healthcare Technologies Inc.
MEDIROM, a holistic healthcare company, operates over 300 wellness salons across Japan, Re.Ra.Ku® being its leading brand, and provides healthcare services. In 2015, MEDIROM entered the health tech business and launched new healthcare programs using an on-demand training app called “Lav®”, which is developed by MEDIROM. MEDIROM also entered the device business in 2020 and has developed a smart tracker “MOTHER Bracelet®”. In 2023, MEDIROM launched REMONY, a remote monitoring system for corporate clients, and has received orders from a broad range of industries, including nursing care, transportation, construction, and manufacturing, among others. MEDIROM hopes that its diverse health-related product and service offerings will help it collect and manage healthcare data from users and customers and enable it to become a leader in big data in the healthcare industry. For more information, visit https://medirom.co.jp/en.
Contact:
Investor Relations Team
E-mail: ir@medirom.co.jp
Forward-Looking Statements Regarding the Company
Certain statements in this press release are forward-looking statements for purposes of the safe harbor provisions under the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements may include estimates or expectations about the Company’s possible or assumed operational results, financial condition, business strategies and plans, market opportunities, competitive position, industry environment, and potential growth opportunities. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “design,” “target,” “aim,” “hope,” “expect,” “could,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “predict,” “project,” “potential,” “goal,” or other words that convey the uncertainty of future events or outcomes. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, levels of activity, performance, or achievements to be different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company’s operations, results of operations, growth strategy and liquidity. More information on these risks and other potential factors that could affect the Company’s business, reputation, results of operations, financial condition, and stock price is included in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including in the “Risk Factors” and “Operating and Financial Review and Prospects” sections of the Company’s most recently filed periodic report on Form 20-F and subsequent filings, which are available on the SEC website at www.sec.gov. The Company assumes no obligation to update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ from those anticipated in these forward-looking statements, even if new information becomes available in the future.
FAQ
How much did MEDIROM (MRM) raise in its January 2025 share offering?
How many outstanding shares does MEDIROM (MRM) have after the January 2025 offering?
What will MEDIROM (MRM) use the proceeds from its 2025 offering for?
What is significant about MEDIROM's (MRM) 2024-2025 public offering?
What is MEDIROM's (MRM) registered capital after the January 2025 registration?
